DefinitionThis section has been translated automatically.
Recombinant antidote for the Factor Xa inhibitors rivaroxaban and apixaban, which was approved in the USA in May 2018 (AndexXa®).
Pharmacodynamics (Effect)This section has been translated automatically.
Andexanet alfa is able to cancel the effect of the Factor Xa inhibitors rivaroxaban (Xarelto®) and apixaban (Eliquis®) in an emergency. This provides an antidote for the Factor Xa inhibitors. The study is based on data from two Phase III studies (ANNEXA-R and ANNEXA-A) in which the safety and efficacy of reversing the effects of rivaroxaban and apixaban were tested in healthy volunteers.
Note(s)This section has been translated automatically.
The preparation Idarucizumab, which cancels out the effect of the thrombin inhibitor dabigatran (Praxdaxa®), has already been approved in Europe and the USA since 2015.
LiteratureThis section has been translated automatically.
- Siegal DM et al (2015) Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015 373:2413-1424.